Send to

Choose Destination
Semin Oncol. 2002 Aug;29(4):389-99.

Adjuvant therapy for patients with high-risk malignant melanoma.

Author information

San Diego Cancer Research Institute, and San Diego Melanoma Research Program, Vista, CA, USA.


The role of adjuvant therapy in the treatment of patients with high-risk malignant melanoma remains an area of intense investigation. The initial enthusiasm for high-dose interferon has been tempered by the results of more recent studies that allow for conflicting interpretations. Vaccine therapy trials have failed to clearly demonstrate a survival benefit, although several trials are currently ongoing. Recent studies of the role of chemotherapy suggest there may be combinations that have a survival benefit which deserve further study. This article will address patient selection and staging workup, and review options for treatment.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center